Galldiks Norbert, Lohmann Philipp, Albert Nathalie L, Tonn Jörg C, Langen Karl-Josef
Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
Neurooncol Adv. 2019 May 28;1(1):vdz010. doi: 10.1093/noajnl/vdz010. eCollection 2019 May-Dec.
Over the past decades, a variety of PET tracers have been used for the evaluation of patients with brain tumors. For clinical routine, the most important clinical indications for PET imaging in patients with brain tumors are the identification of neoplastic tissue including the delineation of tumor extent for the further diagnostic and therapeutic management (ie, biopsy, resection, or radiotherapy planning), the assessment of response to a certain anticancer therapy including its (predictive) effect on the patients' outcome and the differentiation of treatment-related changes (eg, pseudoprogression and radiation necrosis) from tumor progression at follow-up. To serve medical professionals of all disciplines involved in the diagnosis and care of patients with brain tumors, this review summarizes the value of PET imaging for the latter-mentioned 3 clinically relevant indications in patients with glioma, meningioma, and brain metastases.
在过去几十年中,多种正电子发射断层显像(PET)示踪剂已被用于脑肿瘤患者的评估。在临床常规检查中,脑肿瘤患者进行PET成像的最重要临床指征包括识别肿瘤组织,即勾勒肿瘤范围以进行进一步的诊断和治疗管理(如活检、切除或放疗计划),评估对某种抗癌治疗的反应,包括其对患者预后的(预测性)影响,以及在随访时区分与治疗相关的变化(如假性进展和放射性坏死)与肿瘤进展。为服务于参与脑肿瘤患者诊断和护理的各学科医学专业人员,本综述总结了PET成像在胶质瘤、脑膜瘤和脑转移瘤患者上述3个临床相关指征方面的价值。